Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Oral anthelmintic niclosamide has potent in vitro antiviral activity against SARS-CoV-2. Repurposed niclosamide could be a safe and efficacious COVID-19 therapy. OBJECTIVE: To investigate whether niclosamide decreased SARS-CoV-2 shedding and duration of symptoms among patients with mild...

Descripción completa

Detalles Bibliográficos
Autores principales: Cairns, Dana M., Dulko, Dorothy, Griffiths, Jeffrey K., Golan, Yoav, Cohen, Theodora, Trinquart, Ludovic, Price, Lori Lyn, Beaulac, Kirthana R., Selker, Harry P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829666/
https://www.ncbi.nlm.nih.gov/pubmed/35138402
http://dx.doi.org/10.1001/jamanetworkopen.2021.44942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829666/
https://www.ncbi.nlm.nih.gov/pubmed/35138402
http://dx.doi.org/10.1001/jamanetworkopen.2021.44942

Ejemplares similares